Drug intelligence / Profile preview

Dexmedetomidine + sufentanil

Development stage
Phase 4
Lead developer
Orion
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration
Epidural, Intravenous
01

Overview

Dexmedetomidine + sufentanil is a drug combination used in various anesthetic and analgesic applications. This combination leverages the synergistic effects of both medications to provide enhanced pain relief while potentially reducing side effects associated with either drug alone[1][2]. Dexmedetetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Sufentanil is a potent opioid analgesic that acts primarily on μ-opioid receptors. When combined, these drugs demonstrate improved analgesic efficacy compared to either agent used individually[1][8]. The combination is commonly used in various clinical settings including: - Epidural labor analgesia[1] - Postoperative pain management via patient-controlled analgesia (PCA)[2][8] - Anesthesia for surgical procedures[5] - Awake fiberoptic intubation[4] Clinical studies have shown that this combination can reduce the required doses of each individual medication, potentially minimizing adverse effects while maintaining or improving analgesic efficacy[1][6][8].

Other names
dexmedetomidine hydrochloride + sufentanil citrate
02

Targets

MOR (Mu opioid receptor)ADRA2A (α2A)

Beyond the preview

Go deeper on Dexmedetomidine + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexmedetomidine + sufentanil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call